Summary: A case study conducted by Wesper, a home-based sleep diagnostics provider, has demonstrated that its cloud-based platform can reduce the titration time for hypoglossal nerve stimulation (HGNS) in obstructive sleep apnea (OSA) patients by up to 45%. Typically, HGNS … [Read more...]
PAP Cuts Hospitalizations by Nearly a Third in COMISA Patients
Summary: ResMed presented 13 new clinical studies at SLEEP 2024, highlighting findings on insomnia prevalence and the impact of PAP therapy on patients with comorbid insomnia and sleep apnea (COMISA). Key insights include the widespread prevalence of insomnia, reduced hospital … [Read more...]
Eli Lilly’s Weight Loss Drug Zepbound Cuts Sleep Apnea Severity
Summary: Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) reduced the severity of obstructive sleep apnea (OSA) by up to 63% in adults with obesity in two phase 3 trials. The drug improved sleep apnea symptoms in patients using and not using PAP therapy. Based … [Read more...]